Avrion Therapeutics AG incorporated

Avrion Therapeutics AG (AvrionTx) was incorporated in Basel, the hub of the Swiss pharmaceutical industry, on August 17th 2020. The AvrionTx motto is "Correct for Life" and we aspire to bring long-term solutions for neurodegenerative diseases through precision gene therapy.

Avrion Therapeutics was founded in 2020 based on more than 10 years of research from the Brain Mind Institute and Gene Therapy Platform at the Swiss Federal Institute of Technology Lausanne (EPFL) led by the groups of Dr. Bernard Schneider, Prof. Patrick Aebischer and Prof. Brian McCabe. Avrion’s immediate mission is to advance its first product AVR-001 as a treatment for motor neuron disease (amyotrophic lateral sclerosis - ALS) and to develop its other programs of precision gene therapy solutions for neurodegenerative diseases. Avrion’s exclusive gene therapy technology enables delivery of therapeutic gene sequences to discrete cell types in the central nervous system including neurons and astrocytes. Gene therapies can provide benefit through modulation of gene function and typically require a single administration of the treatment. Avrion's first clinical candidate gene therapy product, AVR-001, is preparing to enter IND-enabling studies to treat patients with a form of ALS.